Novartis' medication for skin conditions receives approval in the US
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Source: Reuters
FDA Approval: The U.S. FDA has approved Novartis' oral treatment, Rhapsido, for chronic spontaneous urticaria (CSU), a chronic inflammatory skin disease, providing a new option for patients who do not respond to standard therapies.
Treatment Efficacy and Cost: Rhapsido, which costs $4,521 for a 30-day supply, showed significant improvements in itch severity and hive count in clinical trials, with many patients experiencing relief within weeks. The drug is also being explored for other immune-related conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
